Dr. Reddy's Laboratories (RDY) is planning to launch a cheaper version of Novo Nordisk's (NVO) weight-loss drug, Wegovy, in 87 countries in 2026, Reuters reported Wednesday, citing CEO Erez Israeli's speech at a press conference.
The company could initially launch the generic version of the drug in Canada, Brazil, India, Turkey, and emerging markets, subject to patent expiry. "US and Europe will open later," Israeli said, according to the media outlet.
The company has filed regulatory applications in all the countries involved in the launch, according to the report.
Dr. Reddy's Laboratories didn't immediately respond to a request for comment from MT Newswires.
Shares were up 2.4% in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 14.76, Change: +0.35, Percent Change: +2.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.